Inotuzumab ozogamicin: Preliminary Phase II data

Preliminary data from the open-label, international Phase II Study 2001 trial in 43 evaluable patients who have relapsed or are refractory to rituximab and chemotherapy or anti-CD20 radioimmunotherapy showed that inotuzumab ozogamicin produced an ORR of 53%, including 7 complete responses. The most common grade 3/4 adverse events were thrombocytopenia, neutropenia and lymphopenia. Patients received 1.8 mg/m 2 inotuzumab ozogamicin every 28 days for 4-8 cycles, with dose and/or frequency adjusted based on toxicity. Data were presented at the American Society of Hematology meeting in Orlando. ...